Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025) - Poll - MDSpire

Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

  • By

  • Bing Guo

  • Ge Zhang

  • Shengpeng Sang

  • Xianfen Ma

  • Huanpeng Qi

  • June 2, 2026

  • 0 min

Share

Original Source(s)

Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

  • by Bing Guo, Ge Zhang, Shengpeng Sang, Xianfen Ma, Huanpeng Qi

  • June 2, 2026

Related Content

Ultraviolet radiation as a double-edged regulator of melanocyte function in vitiligo therapy and melanoma carcinogenesis

Sustained complete response to TMEp-CI-M platform in refractory small-cell lung cancer with brainstem metastasis: a case report with over 20 months of disease-free survival

Signals of inequity in the care pathway: rural lab diagnosis, systemic therapy delays, and RAS mutation differences in metastatic colorectal cancer